Login

Ask AI

$HTFL

$57.82 +$0.81 (1.43%) Close

$HTFL Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Company Executives

$HTFL Management Team

Mr. William Weldon

Independent Chairman of the Board

Age 76

Compensation $65.00K USD

Sex Male

Mr. John Farquhar

President

Chief Executive Officer

Director

Age 53

Compensation $2.280M USD

Sex Male

Mr. Vikram Verghese

Chief Financial Officer

Age 41

Compensation $1.695M USD

Sex Male

Dr. Campbell Rogers

Chief Medical Officer

Age 64

Compensation $1.065M USD

Sex Male

Name / Title	Age	Compensation	Sex	Social Media
Mr. William Weldon Independent Chairman of the Board	76	$65.00K USD	Male
Mr. John Farquhar President Chief Executive Officer Director	53	$2.280M USD	Male
Mr. Vikram Verghese Chief Financial Officer	41	$1.695M USD	Male
Dr. Campbell Rogers Chief Medical Officer	64	$1.065M USD	Male

Board of Directors

From the proxy statement filed Apr 29, 2026

Directors

7

serving now

Independent

6 of 6

stated in the proxy; 1 not stated

Average tenure

8.9 years

from year joined

CEO also chairs the board

No

William C. Weldon

Director	Age	On board	Independent	Committees	Other public boards	2025 pay	Source
Julie A. Cullivan	60	2020 6 years	Independent	Audit Committee	Axon Enterprises, Inc.	$292,955
John C.M. Farquhar CEO	54	2022 4 years	Not stated	None stated	None stated	Paid as CEO
Timothy C. Barabe	73	2022 4 years	Independent	Audit Committee · Chair	Cartesian Therapeutics, Inc.	$294,433
Jeffrey C. Lightcap	67	2011 15 years	Independent	Compensation Committee	CareView Communications, Inc., RTI Surgical, Inc.	$509,237
Wayne J. Riley, M.D.	67	2021 5 years	Independent	Compensation Committee · Chair	HCA Healthcare, Inc.	$295,173
Casey M. Tansey	68	2010 16 years	Independent	Nominating and Corporate Governance Committee	Inspire Medical Systems, Inc., Shoulder Innovations, Inc.	$509,237
William C. Weldon Board chair	77	2014 12 years	Independent	Nominating and Corporate Governance Committee · Chair	Fairfax Financial Holdings Limited	$339,662

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

19 disclosed in the proxy filed Apr 29, 2026

Hayfin HeartFlow UK Limited

$ 23,000,000.00

Purchased 2025 Convertible Notes in the 2025 convertible notes offering

With the Company Open in proxy

BCLS Fund III Investments, LP

$ 6,595,648.51

Purchased 2025 Convertible Notes in the 2025 convertible notes offering

With the Company Open in proxy

Timothy C. Barabe

$ 2,000,000.00

Purchased 2025 Convertible Notes in the 2025 convertible notes offering

With the Company Open in proxy

Lonnie M. Smith

$ 1,822,713.44

Purchased 2025 Convertible Notes in the 2025 convertible notes offering

With the Company Open in proxy

HCPCIV 1, LLC

$ 1,460,234.00

Purchased 2025 Convertible Notes in the 2025 convertible notes offering

With the Company Open in proxy

U.S. Venture Partners Funds

funds of which Casey M. Tansey, a director, is a controlling member; own more than 5% of our outstanding capital

$ 811,558.22

Purchased 2025 Convertible Notes in the 2025 convertible notes offering

With the Company Open in proxy

Casey M. Tansey

$ 250,000.00

Purchased 2025 Convertible Notes in the 2025 convertible notes offering

With the Company Open in proxy

Vikram Verghese

$ 144,650.88

Purchased 2025 Convertible Notes in the 2025 convertible notes offering

With the Company Open in proxy

Hayfin HeartFlow UK Limited

lender under the 2024 Credit Agreement; owns more than 5% of our outstanding capital

$23.0 million

2025

Converted $23.0 million of outstanding term loan indebtedness into 2025 Convertible Notes

With the Company Open in proxy

Hayfin HeartFlow UK Limited

lender under prior credit agreement; holder of warrants

Amount not stated

Company issued warrants to purchase 185,407 shares of common stock, later adjusted to additional warrants

With the Company Open in proxy

Hayfin HeartFlow UK Limited

lender under prior credit agreement; holder of warrants

Amount not stated

2025

Hayfin net exercised all outstanding common stock warrants for 1,646,317 shares of common stock

With the Company Open in proxy

BCLS Fund III Investments, LP

$ 99,999,998.18

Purchased 35,081,564 shares of Series F preferred stock in the Series F and F-1 financing

With the Company Open in proxy

The Lonnie and Cheryl Smith Family Trust

trust affiliated with Lonnie M. Smith, a director in 2025 prior to our initial public offering

$ 15,408,505.15

Purchased 8,068,125 shares of Series F-1 preferred stock in the Series F and F-1 financing

With the Company Open in proxy

Hayfin HeartFlow UK Limited

$ 15,136,167.06

Purchased Series F and Series F-1 preferred stock in the Series F and F-1 financing

With the Company Open in proxy

HCPCIV 1, LLC

$ 13,654,851.50

Purchased Series F and Series F-1 preferred stock in the Series F and F-1 financing

With the Company Open in proxy

Wellington Entities

$ 11,885,000.12

Purchased 4,169,444 shares of Series F preferred stock in the Series F and F-1 financing

With the Company Open in proxy

U.S. Venture Partners Funds

funds of which Casey M. Tansey, a director, is a controlling member; own more than 5% of our outstanding capital

$ 9,999,998.68

Purchased 3,508,156 shares of Series F preferred stock in the Series F and F-1 financing

With the Company Open in proxy

William C. Weldon

$ 363,922.46

Purchased Series F and Series F-1 preferred stock in the Series F and F-1 financing

With the Company Open in proxy

Michael Smith

relative of Mr. Lonnie M. Smith, one of our directors in 2025 prior to our initial public offering

Did not exceed $325,000

2023, 2024, and 2025

Non-executive employee of the Company since 2014 with overall cash compensation not exceeding the stated amount for 2023, 2024 and 2025

With the Company Open in proxy

Loading...

Comments